Dr. Ashok Srivastava is Chief medical officer of ClinFomatrix- a Contract analysis Organization (CRO). He was founder Chief medical officer of CareBeyond – A actinotherapy Cancer Center, New Jersey, USA. He has over fifteen years of expertise in drug development, devices development, medical affairs and development of cancer medication and substantiating care; phase I clinical trial – four, and promoting development of cancer medication for solid tumors, hematologictumors. and radiopharmaceutical medication in USA, EU, and Japan. he’s a frontrunner in cancer drug Development Worldwide large and complex section three Clinical Trials in several countries. He contributed to 21-INDs and 7-NDAs of Cancer drugs, acquisition/merger of company and drug for more than $1.2 billion $. He received his clinical, medical coaching & worked at known medical centers and pharmaceutical establishments worldwide; Walter Reed Army Institute of analysis and medical center, Daiichi, Sumitomo, Pharmacia, Pfizer, Eisai oncology, and Spectrum Pharmaceuticals. He received his Clinical, Medical & Business educations from All India Institute of Medical Sciences, New Delhi, India; Academy of Medical Sciences, Czechoslovakia; school of medication Nagasaki University, Nagasaki, Japan, and Pharmaceutical Business at Rutgers University Business Management, New Jersey, USA. He compete key role in dramatic growth of oncology drug – developed cancer drugs- Sutent (Sunitinib), Evoxac (Cevimeline HCl), and liposomal doxorubicin (Myocet) together with Herceptin & Paclitaxel for HER2 positive metastatic breast cancer patients and Latuda (Lurasidone) for schizophrenia he’s one in all the inventors of Japanese encephalitis vaccine (IXIARO) . He has revealed various clinical papers in National and International Journals, abstracts, book chapters and he has two patents. he’s a recipient of diverse National & International prestigious medical awards and recognition from United Nations, Ministry of Health, Japan, and Department of Army, Walter Reed Army medical center and Walter Reed Army Institute of analysis, Washington DC, USA. He served as medical consultant to many pharmaceutical corporations in USA, EU, and India. Dr. Srivastava may be a member of prestigious organizations; America’s prime medical specialist of the years 2007, 2008, 2011, carcinoma Foundation, Indian Society of medicine, yank Society of Clinical medicine, yank Society for Therapeutic Radiology & medicine, yank Association of Cancer analysis, and International Society of lung cancer. Dr. Srivastava may be a strategic medical consultant and board member to many companies in USA for clinical, regulatory drug development. Srivastava is a Leader in Drug Safety, pharmacovigilance of oncology, Hematology, Immuno-Oncology and built international drug safety and pharmacovigilance corporations in USA, and India. Dr. Srivastava was invited as an honorable speaker at drug safety & Pharmacovigilance congress in United Kingdom, China, India and Washington, DC, USA on Jan 2012, 2013, 2017 and presently, in Japan 2019 Dr. Srivastava brought four cancer drugs & a vaccine in an international market for approx. 3 – 3.5 billion $ global sales.
